Document:

Research Agreement

 Exhibit 10.5 
 THIS RESEARCH AGREEMENT is made on 25th September 2006 
 BETWEEN 
  

	(1)	VIA PHARMACEUTICALS INC. 750 Battery Street, Suite 330 San Francisco, CA 94111 (“Company”); and 

  

	(2)	UNIVERSITY OF LIVERPOOL of The Foundation Building, 765 Brownlow Hill Liverpool, L69 7ZX (“University”). 

 WHEREAS 
  

	A	The University has expertise in the field of tachykinin in vitro and in vivo models for different disease states and is able to carry out research in that field.

  

	B	The Company wishes to commission a programme of research in that field to be undertaken by the University. 

 IT IS HEREBY AGREED: 
  

	1.	DEFINITIONS 

 The following terms shall have the
following meanings: 
 “Background Intellectual Property” shall mean any Intellectual Property of either party relevant to
this particular project in existence as at the date of this Agreement or which comes into existence during the Contract Period but which is not generated pursuant to the Study; 
 “Confidential Information” shall mean all information of a confidential nature concerning the Study or disclosed (whether in writing,
orally or by any other means and whether directly or indirectly) by one party (the “Disclosing Party”) to the other party (the “Receiving Party”) whether before or after the date of this Agreement including, without
limitation, any information relating to the Disclosing Party’s products, operations, processes, plans or intentions, laboratory data, other Study data, specifications, Intellectual Property Rights, trade secrets, partnering plans, marketing
plans, market opportunities and business affairs; 

 “Contract Period” shall mean from
1st November 2006 to August 2007; 
 “Intellectual Property” shall mean patents, trade marks, service marks, registered designs, domain names, applications for any of the foregoing, trade and business names, unregistered trade marks and
service marks, Know-How, copyrights, rights in designs, rights in databases, rights in inventions, rights in improvements and rights of the same or similar effect or nature, in any part of the world; 
 “Know-How” shall mean any unpatented technical information (including, without limitation, information relating to inventions,
discoveries, concepts, methodologies, models, research, development and testing procedures, the results of experiments, tests and trials, manufacturing processes, techniques and specifications, quality control data, analyses, reports and
submissions) that is not in the public domain; 
 “Resulting Intellectual Property” shall mean all Intellectual Property
arising from the Study and conceived and/or made by one or more employees, students or other agents of the University; 
 “Researcher” shall mean the post doctoral research assistant of the University to be funded by the Company; 
 “Study” shall mean the study described in Appendix A to be carried out by the Researcher under the direction of Professor John Quinn (“Supervisor”) or of such other members of staff as the Company and the
University shall mutually agree. 
  

	2.	RESEARCH WORK 

  

	 	2.1	The University shall commence the performance of the Study promptly after the commencement date of the Contract Period and shall use reasonable endeavours to perform such Study
substantially in accordance with the terms and conditions of this agreement. The Company and the University may however at any time amend the Study by mutual written agreement. 

  

 2 

	 	2.2	In the event that the Supervisor becomes unable or unwilling to continue the Study, the University shall nominate a substitute, to be approved by the Company. Such approval shall
not be unreasonably withheld or delayed. 

  

	3.	REPORTS AND CONFERENCES 

  

	 	3.1	Written progress reports shall be provided by the University to the Company every 2 months, and a final report shall be submitted by the University within 1 month of the conclusion
of the Contract Period. 

  

	 	3.2	During the term of this Agreement, representatives of the University will meet at appropriate intervals with representative of the Company at times and places mutually agreed upon
to discuss the progress and results as well as ongoing plans, or changes therein, of the Study. 

  

	4.	COSTS, BILLINGS AND OTHER SUPPORT 

  

	 	4.1	It is agreed that the Company shall pay to the University the sum of $50,000 in respect of gross employment costs of the Researcher and other direct and indirect costs of the Study.
The University shall submit invoices to the Company quarterly in advance. All invoices shall become payable thirty (30) days following receipt. Late payment will be subject to interest at the rate of 4% above the base rate from time to time of
Barclays Bank plc. 

  

	 	4.2	Payment will be made payable to “The University of Liverpool” within 30 days of submission of an appropriate invoice by the University. 

  

	 	4.3	University will match this amount via a proof of concept fund and the project will be exempt of FEC costs or overheads. 

  

	5.	PUBLICITY 

 The Company will not use the name of the
University nor of any member of the University’s Study staff in any publicity advertising or news release without the prior written approval of an authorised representative of the University. The University will 

  

 3 

 
not use the name of the Company or any member of the Company’s staff in any publicity without the prior written approval of the Company, unless bound to
do so by reason of some legal, statutory or quasi-statutory obligation. 
  

	6.	CONFIDENTIALITY 

  

	 	6.1	In the course of this Agreement, it is anticipated that each party will learn Confidential Information about the other. Subject to clause 7.1, the Receiving Party shall keep
confidential this Confidential Information, and only disclose or use such Confidential Information where specifically authorised in writing by the Disclosing Party or as may be necessary in connection with the performance of the Study under this
Agreement, or as may be required by law or regulatory authorities. 

  

	 	6.2	Information shall not be considered Confidential Information and the restrictions in clause 6.1 above shall not apply to disclosed information that: 

  

	 	6.2.1	was known by the Receiving Party at the time of disclosure to it by the Disclosing Party, or that according to written proof is independently developed or discovered by the
Receiving Party, after disclosure by the Disclosing Party, without the aid, application or use of any item of the Disclosing Party’s Confidential Information, as evidenced by written records; 

  

	 	6.2.2	is now, or subsequently becomes, through no act or failure to act on the part of the Receiving Party, generally known or available; 

  

	 	6.2.3	is disclosed to the Receiving Party by a third party authorised to disclose it; or 

  

	 	6.2.4	is required by law or by court or administrative order to be disclosed; provided, that the Receiving Party shall have first given prompt notice to the Disclosing Party of such
required disclosure. 

  

 4 

	 	6.3	The provisions of this Clause 6 shall survive for a period of five (5) years from the date of any expiration or termination of this Agreement, however caused.

  

	7.	PUBLICATIONS 

  

	 	7.1	The Company recognises that under University policy the results of the Study should be publishable and agrees that the Supervisor and Researcher engaged in the Study shall be
permitted to present and to publish the methods and results of the Study provided however that the Company shall have been furnished with copies of any proposed publication or presentation at least four weeks in advance of the submission of such
proposed publication or presentation to a journal editor or other third party. The Company shall have the power to delay proposed publication or presentation if in its reasonable opinion such delay is necessary to protect its business interests or
the commercial uses to the Company whether actual or potential of the information derived from the Study. A written reply indicating approval of or delay to disclosure shall be sent by the Company within 14 days of receipt of the request providing
that the delay to disclosure of the results shall in no case exceed three months from the date of receipt by the Company. 

  

	8.	INTELLECTUAL PROPERTY 

  

	 	8.1	For the avoidance of doubt all Background Intellectual Property used in connection with the Study shall remain the property of the party introducing the same.

  

	 	8.2	All rights to Resulting Intellectual Property under the Study shall belong in the first instance to the University and the University hereby grants to the Company a royalty-free non
exclusive licence to commercially exploit such Resulting Intellectual Property. The University also hereby grants the Company a 45 day right of first negotiation for an exclusive worldwide license to Resulting Technology. Under the terms of this
grant, Company will have 45 days from the time that University informs it that it is willing to grant such a right, to reach agreement with University on at least the financial terms for such a license. 

  

 5 

	 	8.3	If the Company requires access to University Background Intellectual Property for the purpose of effectively exploiting the Resulting Intellectual Property then the University,
provided it is free to do so, will grant Company a royalty-free, non exclusive, license under such University Background Intellectual Property solely for the purpose of practising the Resulting Intellectual Property. 

  

	9.	TERMINATION 

  

	 	9.1	This Agreement shall become effective upon the date first herein above written and shall continue in effect for the full duration of the Contract Period unless sooner terminated by
mutual agreement or as set out below. 

  

	 	9.2	Either party may terminate this Agreement with immediate effect by giving notice to the other party if: 

  

	 	9.2.1	the other party is in breach of any provision of this Agreement and (if it is capable of remedy) the breach has not been remedied within [30] days after receipt of written notice
specifying the breach and requiring its remedy; or 

  

	 	9.2.2	the other party becomes insolvent, or if an order is made or a resolution is passed for its winding up (except voluntarily for the purpose of solvent amalgamation or
reconstruction), or if an administrator, administrative receiver or receiver is appointed over the whole or any part of the other party’s assets, or if the other party makes any arrangement with its creditors. 

  

	 	9.3	 Where termination is by mutual agreement or pursuant to clause 9.2 where the Company is the party in breach, then upon any such early termination, the Company shall
pay to the University all reasonable, properly incurred and 

  

 6 

	 	 
non-cancellable expenses and costs incurred up to the date of termination. The University shall have a duty to seek to mitigate such costs as far as is
reasonably possible eg by reutilising staff, materials and services on other projects. 

  

	 	9.4	Upon notice of termination each party shall use all reasonable endeavours to conclude or transfer any uncompleted parts of the Study as expeditiously as possible. The University
shall not undertake further work, incur additional expenses, or enter into further commitments with regard to the Study, except as mutually agreed upon in writing by the Parties. 

  

	10.	FORCE MAJEURE 

  

	 	10.1	If the performance of this Agreement or the Study is prevented, restricted or delayed (either totally or in part) by reason of any cause beyond the reasonable control of the
parties, such as acts of God, explosion, disease, weather, war, insurrection, civil strike, riot or power failure, the University shall, upon giving notice thereof to the Company, be excused from such performance to the extent of such prevention,
restriction or delay; provided, that the University shall use its commercially reasonable efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed.

  

	11.	INDEPENDENT CONTRACTOR 

 Neither party is authorised
nor empowered to act as an agent for the other for any purpose and shall not on behalf of the other enter into any contract, warranty or representation as to any matter. 
  

	12.	LIABILITIES 

  

	 	12.1	 Whilst the University will use all reasonable endeavours to ensure the accuracy of the work performed and any information given the University makes no warranty
express or implied as to accuracy and will not be held responsible for 

  

 7 

	 	 
any consequence arising out of any inaccuracies or omissions unless such inaccuracy or omissions are the result of negligence on the part of the University
or its agents. 

  

	 	12.2	The parties agree and declare that the obligations of the University and its agents shall cease upon delivery of the reports and that no liability whatsoever either direct or
indirect, whether in contract, tort (including negligence) or otherwise shall rest upon them for the effects of any product or process that may be produced or adopted by the Company or any other party notwithstanding that the formulation of such
product or process may be based upon the findings of the Study. 

  

	 	12.3	Neither party shall be liable to the other for any death or injury unless it is caused by the negligence of that party of its agents nor shall it be liable to the other for any
other loss or damage whatsoever unless it is caused by its wilful default of that or its agents. 

  

	13.	INDEMNITY COVER 

  

	 	13.1	The Company shall indemnify the University against all loss, damage, costs and expenses awarded against or incurred by the University in connection with any claim relating to
product liability which is directly connected with the Study, unless such claim results from negligence on the part of the University. 

  

	 	13.2	The Company shall at all times maintain insurance to cover its obligations under this agreement to the reasonable satisfaction of the University and on request shall produce the
policy of insurance to the University, together with evidence of payment of the premium. 

  

 8 

	14.	NOTICES 

  

	 	14.1	Any notice to be given under this Agreement must be in writing, may be delivered to the other party by any of the methods set out in the left hand column below, and will be deemed
to be received on the corresponding day set out in the right hand column: 

  

			
	 Method of service
	  	 Deemed day of receipt

	By hand or courier	  	the day of delivery
		
	By pre-paid first class post	  	the second business day after posting
		
	By recorded delivery post	  	the next business day after posting
		
	By fax (provided the sender’s fax machine confirms complete and error-free transmission of that notice to the correct fax number)	  	the next business day after sending or, if sent before 16.00 (sender’s local time) on the business day it was sent

  

	15.	ASSIGNMENT 

 This Agreement shall not be assigned by
either party without the prior written consent of the parties hereto. Such consent will not be unreasonably withheld. 
  

	16.	ENTIRE AGREEMENT 

 This Agreement, together with all
corresponding Appendices constitutes the entire agreement between the Company and University with respect to the subject matter hereof, and replaces and supersedes any and all prior agreements and/or understandings, whether oral or written, between
the parties with respect to the subject matter of this Agreement. 
  

	17.	AGREEMENT MODIFICATION 

 Any agreement to change the
terms of this agreement in any way shall be valid only if the change is made in writing and approved by mutual agreement of authorised representatives of the parties hereto. 
  

 9 

	18.	INTERPRETATION 

 The descriptive headings of this
Agreement are for convenience only and shall not affect the meaning or construction of any of the provisions of this Agreement. The failure of either party to enforce any provision of this Agreement (including the Appendices) shall not be construed
as a waiver or limitation of that party’s subsequent rights to enforce and compel strict compliance with every provision of this Agreement. To the extent any provision of this Agreement or the application thereof is found by a proper authority
to be invalid or unenforceable, it shall be considered deleted herefrom, and the remainder of this Agreement shall continue in full force and effect. 
  

	19.	GENERAL 

  

	 	19.1	This Agreement may be executed in counterparts, each of which, when executed and delivered, shall be deemed to be an original. 

  

	 	19.2	The Company and the University agree to co-operate to take all necessary steps to ensure compliance with the Data Protection Act 1998 and all relevant regulations enacted thereunder
(or other relevant data protection regulations in any relevant jurisdiction) including ensuring the security of personal data processed as any part of the Study. 

  

	 	19.3	This Agreement and any Appendix does not create any right enforceable by any person not a party to it except that a person who is the permitted successor to or assignee of the
rights of a party is deemed to be a party to this Agreement or any Appendix. This Agreement or any Appendix may be rescinded or varied without the consent of or the need to give any notice to any person not a party to it. 

 

	20.	GOVERNING LAW 

 This Agreement and all terms,
provisions and conditions of the Study and all questions of construction, validity and performance under this Agreement shall be governed by English Law and shall be subject to the exclusive jurisdiction of the English courts. 
  

 10 

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorised officers as of the date
first above written. 
  

	
	Signed by and on behalf of The University of Liverpool
	
	/s/ Colin Cooper
	acting by a duly authorized signatory: MR COLIN COOPER

  

	
	Signed by and on behalf of VIA Pharmaceuticals
	
	/s/ Lawrence K. Cohen
	acting by a duly authorized signatory:

 APPENDIX A 
 STUDY – ARTERIOSCLEROSIS PROJECT 
 Project plan with milestones 
 This project will address the expression and role of the tachykinin pathway in atherosclerosis mechanisms regulating Preprotachykinin A gene (PPTA), which encodes the
neuropeptide substance P, expression in endothelial cells. 
 Month 1-6 
 Generation of mouse double knock-out 
 The NK1 knock out mouse strain will be crossed with an apoE knock out strain
which develops atherosclerosis when fed a high fat diet. A double knock out will be generated. This mouse line will then be evaluated compared to the apoE single knock out with respect to development of atherosclerosis on a high fat diet. To perform
these experiments the mouse strain will be sent to Jackson lab in Sacramento California. 
 Evaluation of tachykinin pathway protein expression in mouse
atherosclerosis 
 VIA will provide sections of mouse aortas with various stages of atherosclerosis for immunohistochemistry studies. Substance P, NK1 and
the transcription factor REST antibodies will be used to evaluate the expression of the tachykinin pathway in atherosclerosis and to determine cell type specificity of that expression. 
 In vitro validation 
 Experimentally this would initially use in vitro models including human endothelial primary and
clonal cell lines to address PPTA expression under basal and stressed conditions. A number of stimuli will be used including ATP and general PKC and PKA activated pathways. PPTA expression will be addressed by quantitative PCR, immunofluorescence,
confocal imaging, immunostaining, reporter gene constructs. In this approach both expression of the gene and synthesis of the peptide will be monitored. Molecules will be screened that are involved in processing the pre-propeptide to the active
peptide substance P. Time course will be done and protein synthesis blocks applied to determine how early PPTA is expressed in response to challenge. This could be done within 6 months, and would be the first milestone that would encourage further
support from VIA or elsewhere. 
 Months 6-9 (In vivo validation) 
 An important model would be the in vivo analysis of tachykinin expression in endothelial cells in response to stress would require use of the lung model and focus on PPTA and substance P expression in response to viral challenge. Substance
P expression is both temporal and in specific non neuronal cell types in initiating the immune response to challenge. We will have a more stringent course on inducible expression specifically highlighting potential expression in endothelial cells or
modulation of endothelial cell function in cells adjacent to substance expression. 

 Project deliverables 
  

	 	•	 	 An evaluation of protein expression in mouse atherosclerosis for tachykinin pathway members. 

  

	 	•	 	 A fully functional in vitro validated model of the tachykinin stimulation early on in a stress response in endothelial cells, making it clinically relevant.

  

	 	•	 	 Generation of a double knock-out mouse strain for NKI/apoE. 

  

	 	•	 	 In vivo validation of this model, enabling a route to screen for compounds against this target specifically to treat arteriosclerosis. 

Financial 
 funds required to complete the proof-of-concept
project 
  

			
	 Budget Item
	  	9 for Costs
months £
	 Post-doctoral RA (point ) TBA net salary
	  	24,270
	 USS+ NI
	  	5,245
		  	 
	 Gross Cost
	  	29,515
		  	 
	 Consumables and Animals
	  	
	 Tissue culture plastics and media
	  	6,000
	 Transfection reagents
	  	1000
	 Mice maintenance for Transgenic colonies for this project. £1000/month
	  	9,000
	 Molecular Biology and PCR reagents
	  	5000
	 Confocal and imaging Analysis
	  	1500
	 Immunohistochem and purchase of Antibodies
	  	3000
		  	 
	 Grand Total
	  	55,015
		  	 

 One half of these costs will be met by Via Pharmaceuticals, an equivalent of $50,000. 
  

 2Patent Rights

 Exhibit 10.6 
 PATENT RIGHTS AND RELATED ASSETS PURCHASE AGREEMENT 
 THIS PATENT RIGHTS AND RELATED ASSETS PURCHASE
AGREEMENT (this “Agreement”), dated as of January 25th, 2007, is by and between VIA PHARMACEUTICALS, INC., a Delaware corporation having an address of 750 Battery St., Suite 330, San Francisco, California 94111 (the
“Acquirer”), and NEURO3D, S.A., a French corporation having an address of 130 rue de la Mer Rouge, F-68200, Mulhouse, France (the “Company”). The Acquirer and the Company are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” Certain other terms are used herein as defined below in Section 1 or elsewhere in this Agreement. 
 Recitals 
 WHEREAS, the Company desires to provide for the sale of patent rights and related assets
related to the Company’s small molecule phosphodiesterase program to the Acquirer, and the Acquirer desires to acquire such patent rights and related assets from the Company, on the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the premises and of the representations, warranties, covenants and agreements herein contained, the receipt and
sufficiency of which is hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	1.	DEFINITIONS. For purposes of this Agreement: 

 “Acquired Assets” means all of the Company’s right, title, and interest in and to all assets used or held for use in connection with the Company’s phosphodiesterase program, consisting of the following assets:
(a) all patents, patent applications and patent registrations (including, without limitation, the Patents), Improvements, modifications, Know-How, trade secrets, developments, inventions (whether patentable or not), invention disclosures,
technology, technical data, specifications, drawings, designs, regulatory filings/approvals/concurrences, notebooks, manufacturing data and technology, analytical and process techniques, research and development data and reports, methods, protocols,
clinical and safety data in both paper and electronic formats, statistical programs, preclinical data, analytical data, batch records, standard operating procedures, analytical standards, metabolites, serum samples, tissue samples, API, compound
stocks, compound databases and other materials and compositions related therewith or useful for the manufacture, use, sale or registration of assets related thereto, and any goodwill associated with any of the foregoing as listed on Annex I;
(b) the Company’s compounds as listed in Annex 1; (c) the Compound Libraries; (d) quantities of materials and reagents that are being, or have been, used in assays in connection with the foregoing, including genetic constructs,
monoclonal antibodies, cell lines, purified proteins, ready assays and expression vectors; . For the purpose of clarification, Acquired Assets shall not include Company’s physical facilities, retention of Company employees or any sales and
marketing distribution system. 
 “Acquirer” is defined above in the preamble. 
 “Action” is defined in Section 8.5. 

 “Affiliates” means, with respect to a particular party, persons or entities controlling,
controlled by or under common control with that party, as well as any officers, directors and majority-owned entities of that party and of its other Affiliates. As used in this definition, the term “control” means either (i) the
possession, directly or indirectly, of the power to direct or to cause the direction of the management of the affairs of a Person or the conduct of the business of a Person, or (ii) the holding of a direct or indirect equity or voting interest
of fifty percent (50%) or more in the Person. 
 “Agreement” means this Agreement and the annexes and exhibits hereto.

 “Bill of Sale” means a Bill of Sale and Assignment conveying the Acquired Assets to the Acquirer (or its nominee) free and clear
of any Encumbrances of any nature whatsoever, in the form and substance set forth as Exhibit A. 
 “Charter Documents” means
an entity’s certificate or articles of incorporation, certificate defining the rights and preferences of securities, articles of organization, general or limited partnership agreement, certificate of limited partnership, joint venture agreement
or similar document governing the entity. 
 “Claim Notice” is defined in Section 8.3. 
 “Claim Response” is defined in Section 8.3. 
 “Closing” is defined in Section 3.1. 
 “Closing Date” is defined in
Section 3.1. 
 “Company” is defined above in the preamble. 
 “Compound Libraries” shall mean the Company’s libraries of small molecule compounds, which consist of both the phosphodiesterase small
molecule inhibitor library of approximately 2,450 compounds. 
 “Confidential Information” is defined in Section 9.

 “Consents” means any consent, waiver, approval, order or authorization of, or registration, declaration or filing with or notice
to, any Governmental Authority or other Person. 
 “Contract” means any written or oral contract, agreement, lease, instrument or
other commitment that is binding on any Person or its property under applicable Law. 
 “Court Order” means any judgment, decree,
injunction, order or ruling of any federal, state, local or foreign court or governmental or regulatory body or authority that is binding on any person or its property under applicable Law. 
 “Co-owners” means Fondation Transplant (former FORENAP), the Université Louis Pasteur (ULP) and the Centre National de la Recherche
Scientifique, (CNRS) who co-owned certain Patents”. 
  

 2 

 “Co-ownership agreements” means the
following agreements: a) agreement between the ULP, the CNRS and the Company dated 29th December 2006 under which the Company has rights to enter into
this Asset Purchase Agreement and is committed to share the Purchase Price with ULP and CNRS; and b) agreement between Fondation Transplant (former FORENAP) and Company under which the Company has rights to enter into this Asset Purchase Agreement.

 “Co-owned Patents” means the Patents co-owned by the Company and CNRS and/or ULP and/or Fondation Transplant (former
FORENAP) described in Appendix II. 
 “Damages” is defined in Section 8.1. 
 “Default” means (a) a breach, default or violation, (b) the occurrence of an event that with or without the passage of time or the
giving of notice, or both, would constitute a breach, default or violation or (c) with respect to any Contract, the occurrence of an event that with or without the passage of time or the giving of notice, or both, would give rise to a right of
termination, renegotiation or acceleration or a right to receive damages or a payment of penalties. 
 “Encumbrances” means any
lien, mortgage, security interest, pledge, restriction on transferability, defect of title or other claim, charge or encumbrance of any nature whatsoever on any property or property interest. 
 “Expiration Date” is defined in Section 8.4. 
 “Governmental Authority” shall mean any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state,
local, municipal, foreign or other government; (c) governmental or quasi governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board,
instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi national organization or body; or (e) individual, entity or body exercising, or entitled to exercise, any
executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. 
 “Governmental Permit” means any governmental permit, license, registration, certificate of occupancy, approval or other authorization. 
 “Improvements” shall mean an improvement, the practice of which literally or equivalently infringes the exclusive rights of the Acquired Assets. 
 “IND” shall mean an Investigational New Drug Application filed with the United States Food and Drug Administration, or the equivalent
application or filing filed with any equivalent agency or governmental authority outside the United States (including any supra-national agency such as in the European Union) necessary to commence human clinical trials in such jurisdiction.

 “IND-Enabling Studies” shall mean the first safety study, pharmacology study or pharmacokinetic study conducted in animals
according to the Good Laboratory Practices required by regulatory Authorities for pharmaceutical products. For the avoidance of doubt, IND-Enabling Studies are those that are required by regulation to be a component of an IND submission to a
regulatory authority and shall not include pilot or similar studies that may be conducted by Acquirer in accordance with Good Laboratory Practices. 
  

 3 

 “Indemnified Party” is defined in Sections 8.1 and 8.2. 
 “Indemnitor” is defined in Section 8.3. 
 “Information” shall mean all tangible and intangible (a) techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, test
data and results (including pharmacological, toxicological and clinical test data and results), analytical and quality control data, results or descriptions, software and algorithms and (b) compounds, compositions of matter, cells, cell lines,
assays, animal models and physical, biological or chemical material. 
 “Inventions” means disclosures, notes, concepts, or
Improvements that are protectable as a trade secret or by the exclusive rights under all United States and foreign patents that have issued or may issue in the future (including utility, utility model and design patents, supplementary protection
certificates, certificates of invention and the like), all patent applications (including applications for utility, utility model and design patents, supplementary protection certificates, certificates of invention and the like), and all
divisionals, continuations, continuations-in-part, reissues, reexaminations, renewals, extensions or additions to any such patents and patent applications, heretofore or hereafter filed or having legal force in any country of the world, and all
inventions and Improvements disclosed therein. 
 “Know-How” shall mean all Information that has not been published or made
publicly available relating to the Acquired Assets that is necessary to discover, make, use, and sell small molecule drugs, or that relates to the Compound Libraries, that is not included in the Patents and that the Company uses or holds for use in
connection with its phosphodiesterase program. 
 “Knowledge” shall mean, with respect to a particular fact or matter, that the
applicable party is actually aware of that fact or matter, or that such party could be expected to discover or otherwise become aware of that fact or matter in reasonable conduct of its business; provided that a party shall be deemed to have
knowledge of (i) any matters set forth in written correspondence or notices addressed to such party and (ii) any matters contained in the files of such party. 
 “Law” means any statute, law, ordinance, regulation, order or rule of any federal, state, local, foreign or other governmental agency or body or of any other type of regulatory body, including those covering
environmental, energy, safety, health, transportation, bribery, record keeping, zoning, antidiscrimination, antitrust, wage and hour, and price and wage control matters. 
 “Liability” means any direct or indirect liability, indebtedness, obligation, claim, loss, damage, deficiency, guaranty or endorsement of or by any person, absolute or contingent, accrued or unaccrued, due
or to become due, liquidated or unliquidated. 
 “Liquidated Claim Notice” is defined in Section 8.3. 
  

 4 

 “Litigation” means any lawsuit, action, arbitration, administrative or other proceeding,
criminal prosecution or governmental investigation or inquiry. 
 “Out-Licenses” means licenses (including standard form licenses),
sublicenses, agreements, contracts, waivers, distributor agreements, reseller agreements, covenants not to sue, rights to receive royalties or any other consideration, permissions or other arrangements (whether written or oral) under which the
Company has granted to any third party the right to use or otherwise exploit the Acquired Assets. 
 “Party” is defined above in
the preamble. 
 “Patents” means (a) the patents and patent applications listed on Annex II attached hereto, (b) any
patents issuing on such patent applications, (c) any continuations, continuations-in-part, divisionals, renewals, extensions, term restorations, reexaminations, and reissues claiming priority to any of the foregoing patents, (d) any and
all foreign patent applications and any patents issuing thereon that are counterparts of patents or patent applications in the foregoing clauses (a) through (c). 
 “Person” means any natural person, corporation, limited liability company, partnership, proprietorship, association, trust or other legal entity. 
 “Prime Rate” is defined in Section 8.3(b). 
 “Purchase Price” is defined in Section 2.2. 
 “Response Period” is defined in
Section 8.3. 
 “Restricted Party” is defined in Section 9.1. 
 “Retained Liabilities” shall mean all Liabilities of the Company, including, without limitation, Liabilities of the Company: (a) that
constitute trade payables; (b) arising under or relating to any Contract; (c) relating to any litigation pending on the date hereof, or instituted hereafter, based in whole or in part on events or conditions occurring or existing in
connection with, or arising out of, or otherwise relating to, the Company or the ownership, possession, use, operation, sale or other disposition at or prior to the Closing of any of the Acquired Assets (or any other rights, properties or assets
owned or used by or associated with the Company at any time at or prior to the Closing); (d) for Taxes, including, without limitation, Taxes arising in connection with the consummation of the transactions contemplated hereby (including any
Taxes arising because the Company is transferring the Acquired Assets); (e) for costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby; and (f) under this Agreement (or under any agreement
between the Company on the one hand and the Acquirer on the other hand entered into on or after the date of this Agreement). 
 “Taxes” means all taxes, duties, charges, fees, levies or other assessments imposed by any French taxing authority (i.e. whether federal, state, local, municipal or foreign) including, without limitation, all net income, gross
income, gross receipts, value-added, excise, withholding, social security, personal property, real estate, sales and use, ad valorem, license, lease, service, severance, stamp, transfer, payroll, employment, unemployment, disability, 

  

 5 

 
severance, customs, duties, alternative, windfall profits, add-on minimum, estimated and franchise taxes or other similar governmental charge or imposition
(including any interest, penalties or additions attributable to or imposed on or with respect to any such Tax). 
 “Tax Return”
means any French and local governmental tax return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof. 
 “Transaction Documents” means this Agreement, the Bill of Sale, and each of the other documents contemplated by this Agreement. 
 “Transactions” means the transactions contemplated by the Transaction Documents. 
 “Unliquidated Claim” is defined in Section 8.3. 
  

	2.	THE PURCHASE AND SALE OF COMPANY ASSETS. 

 2.1
Acquired Assets; No Assumption of Liabilities 
 (a) Purchase of Acquired Assets. On and subject to the terms
and conditions of this Agreement, the Acquirer agrees to purchase from the Company, and the Company agrees to sell to the Acquirer, all of the Acquired Assets for the Purchase Price specified below in Section 2.2. 
 (b) No Assumption of Liabilities. The Acquirer will not assume or have any responsibility with respect to any Liability of the
Company. 
 2.2 Purchase Price. The aggregate purchase price payable by the Acquirer for the Acquired Assets (the “Purchase
Price”) shall be $2,600,000 in U.S. currency. US$1,600,000 of the Purchase Price paid by the Acquirer is in consideration for the Co-owned Patents. The Purchase Price shall be paid by the Acquirer to the Company in two installments as set forth
in Sections 2.2(a) and 2.2(b). 
 (a) The first installment of the Purchase Price shall be paid at the Closing. The aggregate
amount of the first installment of the Purchase Price shall be $1,600,000 in U.S. currency. 
 (b) The second installment of
the Purchase Price shall be paid at the earlier of (i) the initiation by the Acquirer of IND-enabling studies for a Neuro3D Compound; and (ii) the first anniversary of the Closing Date. The aggregate amount of the second installment of the
Purchase Price shall be $1,000,000 in U.S. currency. 
  

	3.	CLOSING. 

 3.1 Closing. The closing of the
sale of the Acquired Assets to the Acquirer (the “Closing”) shall take place at such time and place as determined by the Parties (the “Closing Date”), which shall in no event be more than ten (10) days from the date hereof.

  

 6 

 3.2 Deliveries. At the Closing, 
 (a) the Acquirer shall pay by wire transfer or certified or bank checks of immediately available funds the first installment of the
Purchase Price as contemplated by Section 2.2(a); 
 (b) the Company will execute and deliver to the Acquirer the Bill of
Sale and such other instruments of sale, transfer, conveyance or assignment (including intellectual property transfer documents) as the Acquirer or its counsel may request; and 
 (c) During thirty days following the Closing Date, the Acquirer shall check the completeness of the Acquired Assets. Any claim or request
concerning completeness of the Acquired Assets shall not be made later than thirty days following the Closing Date. 
  

	4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

 The
Company represents and warrants, to and for the benefit of the Acquirer, as follows: 
 4.1 Organization. The Company is a corporation
duly organized, validly existing and in good standing under the Laws of France and is qualified to do business as a foreign corporation in any jurisdiction where it is required to be so qualified. 
 4.2 Authorization. The Company has the absolute and unrestricted right, power and authority to enter into and to perform its obligations under
each of the Transaction Documents to which it is or may become a party; and the execution, delivery and performance by the Company of each such Transaction Document have been duly authorized by all necessary action on the part of the Company and its
stockholders, board of directors and/or other governing body. This Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. Upon the execution of each of the other
Transaction Documents, each of such other Transaction Documents will constitute the legal, valid and binding obligation of the Company, and will be enforceable against the Company in accordance with its terms. 
 4.3 Consents and Approvals. Neither the execution and delivery by the Company of the Transaction Documents to which it is a Party, nor the
performance of the Transactions to be performed by such Party, will require any Consent, constitute a Default or cause any payment obligation (other than a payment obligation arising pursuant to a court-ordered decree of divorce or an agreement or
instrument entered into or given in connection with a divorce proceeding or similar matter) to arise under (a) any Law or Court Order to which the Company is subject, (b) the Charter Documents or bylaws of the Company or (c) any
Contract, Government Permit or other document to which the Company is a party or by which the properties or other assets of the Company may be subject. 
 4.4 Title to Acquired Assets. The Company has good and marketable title to all of the Acquired Assets, free from any Encumbrances. The use of the Acquired Assets is not subject to any Encumbrances, and such use
does not encroach on the property or rights of anyone else. 
  

 7 

 4.5 Certain Personal Property. All tangible personal property listed on Annex I (a) is in
operating condition, reasonable wear and tear excepted, (b) is usable in the ordinary course of the Company’s business, and (c) conforms with any applicable Laws relating to its construction, use and operation. 
 4.6 Legal Proceedings and Compliance with Law. There is no Litigation that is pending or, to the Knowledge of the Company, threatened against the
Company that relates to or might affect the Acquired Assets or that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Transactions. There has been no Default by the Company
under any Laws applicable to the Company that relates to or might affect the Acquired Assets or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Transactions. There is no Court Order to which
the Company, or any of the Acquired Assets, is subject. 
 4.7 Intellectual Property. 
 (a) Rights to the Intellectual Property Assets. The Acquired Assets include all of the intellectual property used or held for use
by the Company in the exploitation, application or enforcement of the phosphodiesterase technology. The Company has not granted any Out-Licenses, whether or not currently exercisable. 
 (b) Quality of the Intellectual Property Assets. All of the Acquired Assets consisting of patents are in full force and effect and
have not been declared invalid or unenforceable by any court of competent jurisdiction, and all of the Acquired Assets consisting of patent applications are pending with the applicable Governmental Authority (collectively, the “Registered
Proprietary Assets”) and no such applications have been abandoned, allowed to lapse, or rejected. Except as disclosed on Schedule 4.7, none of the Registered Proprietary Assets is subject to any Taxes, maintenance fees, responses to official
actions or other actions falling due within 60 days of the date hereof. All of the Acquired Assets are and at all times have been in compliance with all Laws, and all filings, payments and other actions required to be made or taken to maintain such
Acquired Assets in full force and effect have been made by the applicable deadline. The Inventions were not published, patented, offered for sale, or in public use anywhere in the world prior to the filing date of the respective applications
maturing into the respective Acquired Assets. 
 (c) Non-Infringement by the Company. The Company’s ownership
and/or use of the Acquired Assets, including the products, systems, and methods disclosed or claimed in the Acquired Assets, do not, to the Knowledge of the Company, infringe upon, conflict with or otherwise violate any rights of any third party.
The Company has not received notice of and there are no claims that the ownership and/or use of the Acquired Assets infringe upon, conflict with, misappropriate or otherwise violate any rights of any third party, including without limitation any
lawsuits, demand letters, offers of license, interferences, oppositions, reissue proceedings, reexaminations, challenges to inventorship, cancellations or other contested proceedings, nor is there, to the Knowledge of the Company, any valid basis
for the same. 
  

 8 

 (d) Non-Infringement by Third Parties. To the Knowledge of the Company, no third
party is engaging in conduct that infringes upon, conflicts with, dilutes, misappropriates or otherwise violates the Company’s rights in the Acquired Assets. 
 (e) No Limitation on Enforceability. The Company has not entered into any agreements or licenses or created any security interests,
leases, equities, claims, options, restrictions, rights of first refusal, title retention agreements, covenants not to compete or other exceptions to title (whether written or oral) which affect the Acquired Assets. The Company has not granted any
licenses, immunities, covenants not to sue or other rights (whether written or oral) with respect to the Acquired Assets which would provide a third party with a defense to patent or other intellectual property infringement or misappropriation
proceedings, whether in the United States or in any other country. To the Knowledge of the Company there is no information that could reasonably form a basis for invalidating or rendering unenforceable any of the Acquired Assets, and no
interference, opposition, reissue, reexamination or other proceeding of any nature is or has been pending or, to the Knowledge of the Company, threatened, in which the scope, validity or enforceability of any Acquired Asset is being, has been or
could reasonably be expected to be contested or challenged. 
 (f) Protection of the Assets. 
 (i) All commercially reasonable measures have been taken to maintain the confidentiality of all non-public Acquired Assets and all other
information the value of which to the Company is contingent upon maintenance of the confidentiality thereof. Without limiting the generality of the foregoing, each current and former employee, officer, director and stockholder of the Company, and
each former and current consultant and each other independent contractor to the Company who has had access to proprietary information with respect to and/or in use by any the Company, has entered into an agreement suitable to vest all ownership
rights to any of the Acquired Assets conceived, created, made, or reduced to practice by such person, alone or in cooperation with others, in the Company and has entered into an agreement for maintaining the confidential information of the Company.
All of the foregoing agreements are in full force and effect in accordance with their respective terms. 
 (ii) There is to
the Knowledge of the Company no unauthorized use, infringement or misappropriation of the Acquired Assets by any current or former employee, officer, director or stockholder, nor by any current or former consultant or independent contractor to the
Company. 
 4.8 Finder’s Fees. No Person retained by the Company is or will be entitled to any commission or finder’s or
similar fee in connection with the Transactions. 
 4.9 Accuracy of Information. No representation or warranty by the Company in any
Transaction Document, and no information contained herein or therein or in any document delivered pursuant hereto or thereto, including the Schedules hereto, contains any untrue statement of a material fact or omits to state any material fact
necessary in order to make the statements contained herein or therein not misleading. 
  

 9 

 4.10 LIMITATION. THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE GIVEN AND ACCEPTED IN
SUBSTITUTION FOR ANY REPRESENTATION OR WARRANTY WHICH HAVE BEEN MADE BY THE COMPANY (OR THE STAFF OR AGENTS OF THE COMPANY) PRIOR TO THE SIGNING OF THIS AGREEMENT. EXCEPT FOR THE FOREGOING REPRESENTATIONS AND WARRANTIES AND EXCEPT AS OTHERWISE
EXPRESSLY STATED HEREIN, NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS: 
 (A) A WARRANTY OR REPRESENTATION BY THE COMPANY
AS TO THE VALIDITY AND SCOPE OF ANY ACQUIRED ASSETS CONSISTING OF PATENTS; 
 (B) A WARRANTY OR REPRESENTATION BY THE COMPANY
THAT ANYTHING MADE, USED, SOLD, OFFERED FOR SALE, OR IMPORTED UNDER THE PATENTS INCLUDED IN THE ACQUIRED ASSETS IS OR WILL BE FREE FROM INFRINGEMENT OF PATENTS OF THIRD PARTIES; 
 (C) AN OBLIGATION ON THE PART OF COMPANY TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR INFRINGEMENTS OF ANY OF THE
PATENTS INCLUDED IN THE ACQUIRED ASSETS; OR 
 (D) A WARRANTY OR REPRESENTATION THAT THE ACQUIRED ASSETS CONSISTING OF PRODUCT
DATA ARE FIT FOR A PARTICULAR PURPOSE. 
  

	5.	REPRESENTATIONS AND WARRANTIES OF THE ACQUIRER. 

 The Acquirer represents and warrants, to and for the benefit of the Company, as follows: 
 5.1 Organization. The Acquirer is
a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation. 
 5.2
Authorization. The Acquirer has the absolute and unrestricted right, power and authority to enter into and to perform its obligations under each of the Transaction Documents to which it is or may become a party; and the execution, delivery
and performance by the Acquirer of each such Transaction Document have been duly authorized by all necessary corporate action on the part of the Acquirer. This Agreement constitutes the legal, valid and binding obligation of the Acquirer,
enforceable against the Acquirer in accordance with its terms. Upon the execution of each of the other Transaction Documents, each of such other Transaction Documents will constitute the legal, valid and binding obligation of the Acquirer, and will
be enforceable against the Acquirer in accordance with its terms. 
 5.3 Consents and Approvals. Neither the execution and delivery by
the Acquirer of the Transaction Documents to which it is a Party, nor the performance of the Transactions by the Acquirer, will require any Consent, or constitute a Default or cause any payment obligation to arise under (a) any Law or Court
Order to which the Acquirer is subject, (b) the Charter Documents or bylaws of the Acquirer or (c) any Contract, Governmental Permit or other document to which the Acquirer is a party or by which the properties or other assets of the
Acquirer may be subject. 
  

 10 

 5.4 Legal Proceedings. There is no Litigation that is pending or, to the knowledge of the
Acquirer, threatened against the Acquirer that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Transactions. There has been no Default by the Acquirer under any Laws
applicable to the Acquirer that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the Transactions. There is no Court Order to which the Acquirer is subject that may have the effect of preventing,
delaying, making illegal or otherwise interfering with, any of the Transactions. 
 5.5 Finder’s Fees. No Person retained by the
Acquirer is or will be entitled to any commission or finder’s or similar fee in connection with the Transactions. 
  

	6.	TAXES. 

 6.1 Tax Obligations. The Company
shall timely pay to the French authorities all transfer, documentary, sales, use, stamp, registration, recording and other Taxes and fees arising from or relating to the Transactions, and the Company shall, at its own expense, file to the French
authorities all necessary Tax Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp, registration, and other Taxes and fees. If required by applicable Law, the Acquirer and the Company will join in the
execution of any such Tax Returns and other documentation. 
  

	7.	POST CLOSING COVENANTS. 

 7.1 Further Assurances;
Enforcement; Power of Attorney 
 (a) The Acquirer hereby acknowledges that the Company is discontinuing active
operations. However, Company will cooperate with Acquirer in the provision of financial information regarding its past activities if Acquirer is obligated to do so by law or regulation. During the period of continued operation of the Company (but in
no event less than three months following the date hereof), and solely to extent possible thereafter: 
 (i) The Company
agrees that, from time to time, at the Acquirer’s request and without further consideration, the Company will execute and deliver such additional instruments of transfer and take such other actions as the Acquirer may require to more
effectively transfer ownership of the Acquired Assets to the Acquirer, including but not limited to patent assignments or other transfer instruments with applicable Governmental Authorities. In addition, the Company shall cooperate with the Acquirer
with respect to facilitating communication and interaction with any inventor of any patent (other than inventors of the Co-owned Patents which are in the employ of any Co-owner) or patent application included in the Acquired Assets that is
reasonable and necessary for the Acquirer to (i) perfect or maintain its ownership rights in such patent or patent applications. 
 (ii) The Company will execute all documents for the registration of the Patents in any and all countries, as the Acquirer may desire. 
 (iii) If any Registered Proprietary Asset is infringed by a third party in any country, the Company, upon first having knowledge of such
infringement, or knowledge of a reasonable probability of such infringement, shall promptly notify the Acquirer in writing. The notice shall set forth the known facts of such infringement in reasonable detail and provide any other evidence of such
infringement available to the Company. 
  

 11 

 (b) In the event the Acquirer is unable, after reasonable effort, to secure the
Company’s signature on any document or documents needed to apply for or prosecute any patent, or other right or protection relating to the Acquired Assets under the Agreement, the Company hereby appoints the Acquirer, its successors and
assigns, as the Company’s true and lawful attorney, with full power of substitution, in the Company’s name but on behalf and for the benefit of the Acquirer, its successors and assigns to execute and file any such application or
applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, or similar protections thereon with the same legal force and effect as if executed by the Company. The Company hereby declares that the
foregoing powers are coupled with an interest and are and shall be irrevocable by the Company or by its dissolution or in any manner or for any reason whatsoever. 
  

	8.	INDEMNIFICATION. 

 8.1 By the Company. From
and after the Closing Date, to the extent provided in this Section 8, the Company shall, indemnify and hold harmless the Acquirer, and its successors and assigns, and its officers and directors (each, an “Indemnified Party”) from and
against any Liabilities, claims, demands, judgments, losses, costs, damages or expenses whatsoever (including reasonable attorneys’, fees incurred by such Indemnified Party in connection therewith) (collectively, “Damages”) that such
Indemnified Party may sustain, suffer or incur and that result from, arise out of or relate to (a) any breach of any representation, warranty, covenant or agreement of the Company contained in this Agreement, whether or not involving a
third-party claim, (b) any Litigation affecting the Company or the Acquired Assets that arose from any matter or state of facts existing prior to the Closing, (c) any Retained Liabilities, or (d) the failure by the Company to comply
with the provisions of the laws of any jurisdiction relating to the transfer of assets which may be applicable to the transfer of the Acquired Assets; provided that the foregoing indemnification shall not apply to any Damage to the extent such
Damage is caused by the breach of this Agreement or the negligence or willful misconduct of the Acquirer or its Affiliates and their current or former employees, officers and directors or is otherwise subject to an obligation by Acquirer to
indemnify Company under section 8.2. 
 8.2 By the Acquirer. From and after the Closing Date, to the extent provided in this
Section 8, the Acquirer shall indemnify and hold harmless the Company, the Company Stockholders, their heirs, legal representatives, successors and assigns (each, an “Indemnified Party”) from and against any Damages that such
Indemnified Party may sustain, suffer or incur and that result from, arise out of or relate to (a) any breach of any representation, warranty, covenant or agreement of the Acquirer contained in this Agreement, whether or not involving a
third-party claim, (b) the failure by the Acquirer to comply with the provisions of the laws of any jurisdiction relating to the transfer of assets which may be applicable to the transfer of the Acquired Assets, or (c) any liability
arising out of the development or exploitation of the Acquired Assets by the Acquirer or its Affiliates including without limitation clinical trials and sales of a product, other than any liability arising out of or relating to any matter or state
of facts existing prior to the Closing Date; provided that the foregoing indemnification shall not apply to any Damage to the extent such Damage is caused by the breach of this Agreement or the negligence or willful misconduct of the Company or its
Affiliates and their current or former employees, officers and directors or is otherwise subject to an obligation by the Company to indemnify the Acquirer under section 8.1. 
  

 12 

 8.3 Procedure for Claims. 
 (a) An Indemnified Party that desires to seek indemnification under any part of this Section 8 shall give notice (a “Claim
Notice”) to each Party responsible or alleged to be responsible for indemnification hereunder (an “Indemnitor”) prior to any applicable Expiration Date specified below. Such notice shall briefly explain the nature of the claim and
shall specify the amount thereof. If the matter to which a claim relates shall not have been resolved as of the date of the Claim Notice, the Indemnified Party shall estimate the amount of the claim in the Claim Notice, but also specify therein that
the claim has not yet been liquidated (an “Unliquidated Claim”). If an Indemnified Party gives a Claim Notice for an Unliquidated Claim, the Indemnified Party shall also give a second Claim Notice (the “Liquidated Claim Notice”)
within 60 days after the matter giving rise to the claim becomes finally resolved, and the Second Claim Notice shall specify the amount of the claim. Each Indemnitor to which a Claim Notice is given shall respond to any Indemnified Party that has
given a Claim Notice (a “Claim Response”) within 20 days (the “Response Period”) after the later of (i) the date that the Claim Notice is given or (ii) if a Claim Notice is first given with respect to an Unliquidated
Claim, the date on which the Liquidated Claim Notice is given. Any Claim Notice or Claim Response shall be given in accordance with the notice requirements hereunder, and any Claim Response shall specify whether or not the Indemnitor giving the
Claim Response disputes the claim described in the Claim Notice. If any Indemnitor fails to give a Claim Response within the Response Period, such Indemnitor shall be deemed not to dispute the claim described in the related Claim Notice. If any
Indemnitor elects not to dispute a claim described in a Claim Notice, whether by failing to give a timely Claim Response or otherwise, then the amount of such claim shall be conclusively deemed to be an obligation of such Indemnitor. 
 (b) If any Indemnitor shall be obligated to indemnify an Indemnified Party hereunder, such Indemnitor shall pay to such Indemnified Party
within 30 days after the last day of the Response Period the amount to which such Indemnified Party shall be entitled. If the Acquirer shall be the Indemnified Party, it shall seek indemnification directly from the Company for the payment of any
Damages. If the Company or a stockholder shall be the Indemnified Party, he, she or it shall seek indemnification directly from the Acquirer. If any Indemnified Party fails to receive all or part of any indemnification obligation when due, then such
Indemnified Party shall also be entitled to receive from the applicable Indemnitor interest on the unpaid amount for each day during which the obligation remains unpaid at an annual rate equal to the applicable short term federal rate for federal
income tax purposes in effect on the date of expiration of said 30-day period (“Prime Rate”), and the Prime Rate in effect on the first business day of each calendar quarter shall apply to the amount of the unpaid obligation during such
calendar quarter. 
 8.4 Claims Period. Any claim for indemnification under this Section 8 shall be made by giving a Claim Notice
under Section 8.3 on or before the applicable “Expiration Date” specified below in this Section 8.4, or the claim under this Section 8 shall be invalid. The following claims shall have the following respective
“Expiration Dates”: (a) for a period of 

  

 13 

 
twenty (20) years after the Closing Date —any claim for Damages related to (i) a breach of any representations or warranties in Sections 4.2
or 4.4, and (ii) a breach of any representation or warranty that was untrue when made with an intent to mislead or defraud; and (b) the second anniversary of the Closing Date—any other claims. If more than one of such Expiration Dates
applies to a particular claim, the latest of such Expiration Dates shall be the controlling Expiration Date for such claim. So long as an Indemnified Party in good faith gives a Claim Notice for an Unliquidated Claim on or before the applicable
Expiration Date, such Indemnified Party shall be entitled to pursue its rights to indemnification regardless of the date on which such Indemnified Party gives the related Liquidated Claim Notice. 
 8.5 Third Party Claims. An Indemnified Party that desires to seek indemnification under any part of this Section 8 with respect to any
actions, suits or other administrative or judicial proceedings (each, an “Action”) that may be instituted by a third party shall give each Indemnitor prompt notice of a third party’s institution of such Action. After such notice, any
Indemnitor may, or if so requested by such Indemnified Party, any Indemnitor shall, participate in such Action or assume the defense thereof, with counsel satisfactory to such Indemnified Party; provided, however, that such Indemnified Party shall
have the right to participate at its own expense in the defense of such Action; and provided, further, that the Indemnitor shall not consent to the entry of any judgment or enter into any settlement, except with the written consent of such
Indemnified Party (which consent shall not be unreasonably withheld), that (a) fails to include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all Liability in respect of any
such Action or (b) grants the claimant or plaintiff any injunctive relief against the Indemnified Party. Any failure to give prompt notice under this Section 8.5 shall not bar an Indemnified Party’s right to claim indemnification
under this Section 8, except to the extent that an Indemnitor shall have been harmed by such failure. 
 8.6 Limitation of
Liability. Neither Party shall be liable to the other for consequential, indirect or punitive damages. For the avoidance of doubt, no Party can recover from the other Party more than once for a single cause of action under indemnity granted by
the Indemnitor pursuant to this Agreement. The foregoing sentence shall not be construed to preclude recovery in respect of multiple claims arising from a single event or series of events. Neither party shall have liability with respect to any
breach of any such Party’s representations and warranties under this Agreement for any individual item where the Damages relating thereto is less than ten thousand Euros (€10,000), but when a Damages exceeds such amount then the Indemnitor
shall be liable for the entire amount of the Damages. Each Party shall take and shall cause its Affiliates to take all reasonable steps to mitigate any Damages. The cumulative amount of Damages awarded to the Acquirer shall not exceed the Purchase
Price actually paid by Acquirer; except for Damages that the Acquirer (or any Acquirer Indemnified Party) may incur and that result from, arise out of or relate to (a) any Litigation affecting the Company or the Acquired Assets that arises from
any matter or state of facts existing prior to the Closing, or (b) any Retained Liabilities. 
  

	9.	CONFIDENTIALITY. 

 9.1 Confidentiality. For a
period of twenty years (20) after the Closing, the Company (“Restricted Party”) shall not divulge, communicate or use in any way, any trade secrets or other 

  

 14 

 
confidential information related to the Acquired Assets (“Confidential Information”). The Restricted Party shall, and shall cause its subsidiaries,
Affiliates, officers, directors, employees, accountants, counsel, financial advisors and other representatives and agents, to treat and hold as such all of the Confidential Information, refrain from disclosing or using any of the Confidential
Information except in connection with this Agreement and the Transactions, and except as otherwise permitted hereunder or as may be required by Law, deliver promptly to the Acquirer or destroy, at the request and option of the Acquirer, all tangible
embodiments (and all copies) of the Confidential Information which are in the possession of such Restricted Party. In the event that the Restricted Party is requested or required (by request for information or documents in any legal proceeding,
interrogatory, subpoena, civil investigative demand, or similar legal process) to disclose any Confidential Information, the Restricted Party will notify the Acquirer promptly of the request or requirement so that the Acquirer may seek an
appropriate protective order or waive compliance with the provisions of this Section 9.1. If, in the absence of a protective order or the receipt of a waiver hereunder, the Restricted Party is compelled to disclose any Confidential Information
or else stand liable for contempt, the Restricted Party may disclose the Confidential Information; provided, however, that the Restricted Party shall use its reasonable efforts to obtain, at the reasonable request of the Acquirer, an order or other
assurance that confidential treatment will be accorded to such portion of the Confidential Information required to be disclosed as the Acquirer shall reasonably designate. 
 9.2 Injunctive Relief. In the event of any breach or threatened breach by the Restricted Party of any provision of this Section 9, the
Acquirer shall be entitled to injunctive or other equitable relief, restraining such Party from using or disclosing any Confidential Information in whole or in part, or from engaging in conduct that would constitute a breach of the obligations of a
Restricted Party under this Section 9. Such relief shall be in addition to and not in lieu of any other remedies that may be available, including an action for the recovery of damages. In the event of Litigation involving this Section 9,
if a court of competent jurisdiction determines that the scope of this Section 9 is too broad in any respect, then the scope shall be deemed to be reduced or narrowed to such scope as is found lawful and reasonable by such court. 
  

	10.	MISCELLANEOUS. 

 10.1 Press Releases and
Announcements. Except as may be required by applicable securities Laws or stock exchange requirements, no Party shall issue any press release or public announcement relating to the subject matter of this Agreement prior to, at or about the
Closing without the prior written approval of the Acquirer, which written approval will not be unreasonably withheld by each Party; provided, however, that any Party may make any public disclosure it believes in good faith is required by Law or
regulation (in which case the disclosing Party will advise the other Parties prior to making the disclosure). 
 10.2 Purchase of Assets
from Co-owners. Without in any way limiting the representations and warranties of the Company in this Agreement (including, without limitation, those contained in Section 4.3 and 4.4), each of the Parties acknowledges that certain of the
Acquired Assets (the Co-owned Patents) were co-owned by the Company and the Co-owners prior to the consummation of the purchase of such Acquired Assets by the Company from the Co-owners pursuant to the Co-ownership Agreements. 
  

 15 

 10.3 No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any
person other than the Parties and their respective successors and permitted assigns. 
 10.4 Contents of Agreement. This Agreement,
together with the other Transaction Documents, sets forth the entire understanding of the Parties hereto with respect to the Transactions and supersedes all prior agreements or understandings among the Parties regarding those matters. 
 10.5 Amendment, Parties in Interest, Assignment, Etc. This Agreement may be amended, modified or supplemented only by a written instrument duly
executed by each of the Parties hereto. If any provision of this Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision
hereof, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, legal
representatives, successors and permitted assigns of the Parties hereto. No Party hereto shall assign this Agreement or any right, benefit or obligation hereunder without the consent of the other Party; provided, however, that without the prior
consent of the other Party (a) the Acquirer may assign any or all of its rights, benefits or obligations herein to any Affiliate and (b) that either Party hereto shall have the right to assign this Agreement to any successor of all or
substantially all of its business. Any term or provision of this Agreement may be waived at any time by the Party entitled to the benefit thereof by a written instrument duly executed by such Party. The Parties hereto shall execute and deliver any
and all documents and take any and all other actions that may be deemed reasonably necessary by their respective counsel to complete the Transactions. 
 10.6 Interpretation. Unless the context of this Agreement clearly requires otherwise, (a) references to the plural include the singular, the singular the plural, the part the whole, (b) references to
any gender include all genders, (c) “or” has the inclusive meaning frequently identified with the phrase “and/or,” (d) “including” has the inclusive meaning frequently identified with the phrase “but not
limited to” and (e) references to “hereunder” or “herein” relate to this Agreement. The section and other headings contained in this Agreement are for reference purposes only and shall not control or affect the
construction of this Agreement or the interpretation thereof in early respect. Annex, section, subsection, schedule and exhibit references are to this Agreement unless otherwise specified. 
 10.7 Incorporation of Exhibits, Annexes, and Schedules. The Exhibits, Annexes, and Schedules identified in this Agreement are incorporated herein
by reference and made a part hereof. 
  

 16 

 10.8 Notices. All notices that are required or permitted hereunder shall be in writing and shall
be sufficient if personally delivered or sent by facsimile or reputable delivery or courier service. Any notices shall be deemed given upon the earlier of (a) the date when received, (b) the day when sent by facsimile, (d) the third
day after the date when sent by reputable delivery or courier service, to the address or fax number set forth below, unless such address or fax number is changed by notice to the other Party hereto: 
 If to the Acquirer: 
 VIA Pharmaceuticals,
Inc. 
 750 Battery Street, Suite 330 
 San Francisco, CA 94111 
 Attention: Chief Executive Officer 
 Facsimile: (415) 283-2201 
 If to the
Company: 
 Neuro3D, S.A. 
 130
rue de la Mer Rouge, F-68058 
 Mulhouse, Cedex 2, France 
 Attention: Chief Executive Officer 
 And to: 
 Maître Luc BARNY 
 15, boulevard
Clemenceau 
 67 000 Strasbourg, France 
 Facsimile: + 33 388 36 34 38 
 10.9 Governing Law; Submission to Jurisdiction. 
 (a) ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY
JURISDICTION OTHER THAN THE STATE OF NEW YORK. NOTWITHSTANDING THE FOREGOING, ALL QUESTIONS CONCERNING THE PERSONAL LIABILITY OF THE SHAREHOLDERS OF THE COMPANY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF FRANCE. 
 (b) Any legal action or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement may be
brought or otherwise commenced in any state or federal court located in the State of New York. Each party to this Agreement: 
 (i) expressly and irrevocably consents and submits to the jurisdiction of each state and federal court located in the State of New York (and each appellate court located in such State) in connection with any such legal proceeding;

 (ii) agrees that each state and federal court located in the State of New York shall be deemed to be a convenient forum;
and 
 (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding commenced in any
state or federal court located in the State of New 

  

 17 

 
York, any claim that such party is not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient
forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced in or by such court 
 10.10 Expenses. Each of the Parries and the Company will bear his, her or its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement and the Transactions.

 10.11 Recordation of this Agreement. It is understood and acknowledged by both parties to this Agreement that certain countries may
require that this Agreement be recorded. The Company shall, at the Company’s expense, promptly cause this Agreement to be recorded in France. The Acquirer shall be responsible for the recordation costs in any other jurisdiction in which the
Acquirer determines to record this Agreement. 
 10.12 Counterparts. This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original but all of which together will constitute one and the same instrument. 
  

 18 

 IN WITNESS WHEREOF, this Agreement has been executed by the Parties hereto as of the day and year first
written above. 
  

					
	VIA PHARMACEUTICALS, INC.
		
	By:	 	/s/ Lawrence K. Cohen
		 	Name:	 	Lawrence K. Cohen
		 	Title:	 	CEO

  

					
	NEURO3D, S.A.
		
	By:	 	/s/ Charles Woler
		 	Name:	 	Charles Woler
		 	Title:	 	CEO

  

 19 

 ANNEX I 
 Patent Rights and Related Assets 
 Patents: 
  

									
	PDE 4 inh.:
2,3 / 1,4 BZD	  	June 7, 2001	  	PCT: published as WO
02/098865 National/
Regional phases
completed: EP (LT-LV),
US, JP, CA, AU, IN, ZA,
IL, and NZ	  	EP: Response to 1st Office
Action (restriction to 1,4
BZD, divisional 2,3 BZD
still possible) NZ:
Response to Office Action
(restriction to 1,4 BZD)	  	 B0087
  
 (ND1251)

					
	PDE2 inh.:
1,4 BZD	  	Oct. 30, 2002	  	FR: pending published as FR 2846653 PCT: published as WO2004/041258 National/Reg. Phases in: EP, US, JP, AU, CA, IL, IN, JP, ZA, and NZ	  	EP: 2nd Office Action -due date: Feb. 26, 2007 (unity of invention acknowledged, Novelty/Priority objections raised) NZ: Office Action	  	B0171  
 (ND7001)

					
	PDE2 inh.:
7-aryl-1,4 BZD	  	Dec. 23, 2003	  	EP: published as EP 1548011 PCT: published as WO2005/063723 National/Reg. Phases in: EP, US, JP, AU, CA, CN, IL, IN, JP, ZA, and EA	  		  	B0215  
 (ND2791)

  

 20 

									
	 7-aryl 6,8-
 alkoxy BZD
	  	August 3, 2005	  	 European priority application filed EP 05 291658
 Unpublished
 PCT application filed Unpublished
	  	PCT application
filed on Aug. 2,
2006	  	B0305  
 (ND2112)

	 BZD (PDE4)
	  		  	To be filed	  		  	B0537  
 (ND2698)

  

 21 

																									
	 Reference
	 	Titre	 	Dépôt Initial	 	Extension (PCT)	 	Phases nationales	 	Publication de la demande	 	Examens – Annuitées Échéances
	 	 	 	 	N°	 	Date	 	N°	 	Date	 	Pays	 	Date	 	N°	 	Date	 	Statut	 	Date	 	Annuités
		 	Inhibiteurs des phosphodies-	 	FR 01 07458	 	07/06/2001	 		 		 		 		 		 		 	Abandonné	 		 	
		 	térases des nucléotides	 		 		 	PCT/FR02/01952	 	07/06/2002	 		 		 	WO 02/098865	 	12/12/2002	 		 		 	
		 	cycliques, dérivés de	 		 		 		 		 	AU 2002317910	 	07/06/2002	 		 		 	en examen	 		 	07/06/07
		 	benzodiazépines, préparation	 		 		 		 		 	CA 2,446,696	 	07/06/2002	 		 		 	Req. Examen	 	07/06/2007	 	07/06/07
		 	et utilisations	 		 		 		 		 	EP 02 747514.4	 	07/06/2002	 	EP 1 392 663	 	03/03/2004	 	LO	 	17/03/2007	 	30/06/2007
		 		 		 		 		 		 	HK 04 106679.1	 	03/09/2004	 	HK 1 065 531	 	25/02/2005	 		 		 	07/06/2010
	 0087
	 		 		 		 		 		 	IL 159105	 	07/06/2002	 		 		 	LO	 	20/04/2007	 	
		 		 		 		 		 		 	IN 1028/MUMNP/2003	 	07/06/2002	 		 		 	délivré
N°200674	 		 	07/06/07
		 		 		 		 		 		 	JP 2003-501989	 	07/06/2002	 	JP 2005-503356	 	03/02/2005	 	en examen	 		 	
		 	Titulaire	 		 		 		 		 	NZ 529582	 	07/06/2006	 		 		 	délivré
N°1528	 		 	07/06/2008
		 	NEURO3D	 		 		 		 		 	US 10/479,000	 	07/06/2002	 	US 2004-0152888	 	05/08/2004	 	LO	 	23/01/2007	 	
		 		 		 		 		 		 	ZA 2004/0057	 	07/06/2002	 	ZA 2004/0057	 	21/02/2005	 		 		 	07/06/2007

  

 22 

																									
	 Reference
	 	Titre	 	Dépôt Initial	 	Extension (PCT)	 	Phases nationales	 	Publication de la demande	 	Examens – Annuitées Échéances
	  	 	 	 	N°	 	Date	 	N°	 	Date	 	Pays	 	Date	 	N°	 	Date	 	Statut	 	Date	 	Annuités
		 	Inhibiteurs des phosphodies-	 	FR 02 13607	 	30/10/2002	 		 		 		 		 	FR 2 846 653	 	07/05/2004	 	en déliverance	 		 	31/10/2007
		 	térases des nucléotides cycliques,	 	US 60/455,874	 	20/03/2003	 		 		 		 		 		 		 	Expiré	 		 	
		 	préparation et utilisations	 		 		 	PCT/FR02/03247	 	30/10/2003	 		 		 	WO 04/041258	 	21/05/2004	 		 		 	
		 		 		 		 		 		 	AU 2003288352	 	30/10/2003	 		 		 	Req. Examen	 	07/05/2007	 	30/10/2008
	 80171
	 	Titulaires	 		 		 		 		 	CA 2,503,716	 	30/10/2003	 		 		 	Req. Examen	 	30/10/2008	 	30/10/2007
		 	NEURO3D	 		 		 		 		 	EP 03 780257	 	30/10/2003	 	EP 1 556 055	 	27/07/2005	 	LOs	 	26/02/2007
14/03/2007	 	31/10/2007
		 	ULP	 		 		 		 		 	HK 05 108879.4	 	06/10/2005	 	HK 1079084	 	31/03/2006	 		 		 	31/10/2011
		 	CNRS	 		 		 		 		 	IL 168042	 	30/10/2003	 		 		 	en cours	 		 	
		 	FORENAP	 		 		 		 		 	IN 1310/DELNP/2005	 	30/10/2003	 		 		 	en cours	 		 	
		 		 		 		 		 		 	JP 2005-502123	 	30/10/2003	 	JP 2005-509832	 	23/03/2006	 	en examen	 		 	
		 		 		 		 		 		 	NZ 540167	 	30/10/2003	 		 		 	Accord final	 	18/02/2007	 	
		 		 		 		 		 		 	US 10/533,157	 	30/10/2003	 	US 2006-0128695	 	15/06/2006	 		 		 	
		 		 		 		 		 		 	ZA 2005/5412	 	30/10/2003	 		 		 	Délivré N°
2005/5412	 		 	31/10/2007

  

 23 

																									
	 Reference
	 	Titre	 	Dépôt Initial	 	Extension (PCT)	 	Phases nationales	 	Publication de la
demande	 	Examens – Annuitées Échéances
	 	 	 	 	N°	 	Date	 	N°	 	Date	 	Pays	 	Date	 	N°	 	Date	 	Statut	 	Date	 	Annuités
		 	Benzo[1,4]diazepin-2-one	 	EP 03 293309.5	 	23/12/2003	 		 		 		 		 	EP 1 548 011	 	29/06/2005	 	en examen	 		 	31/12/2007
		 	Derivatives as phosphodiesterase	 		 		 	PCT/IB04/004362	 	23/12/2004	 		 		 	WO 05/063723	 	14/07/2005	 		 		 	
		 	PDE2 inhibitors, preparation and	 		 		 		 		 	AU 2004309173	 	23/12/2004	 		 		 	Req. Examen	 	23/12/2009	 	23/12/2009
		 	therapeutic use thereof	 		 		 		 		 	BR PI0418099-2	 	23/12/2004	 		 		 	Req. Examen	 	23/12/2007	 	23/12/2007
	 80215
	 		 		 		 		 		 	CA 2,548,318	 	23/12/2004	 		 		 	Req. Examen	 	23/12/2009	 	23/12/2007
		 		 		 		 		 		 	CN 200480038085.7	 	23/12/2004	 		 		 	en examen	 		 	
		 		 		 		 		 		 	EA 200601212	 	23/12/2004	 		 		 	en examen	 		 	
		 	Titulaire	 		 		 		 		 	EP 04 8066522.1	 	23/12/2004	 	EP 1 697 332	 	06/09/2006	 	en examen	 		 	31/12/2007
		 	NEURO3D	 		 		 		 		 	N° en attente	 	23/12/2004	 		 		 	en cours	 		 	
		 		 		 		 		 		 	IN 2955/DLNP/2006	 	23/12/2004	 		 		 	en examen	 		 	
		 		 		 		 		 		 	JP 2006-546406	 	23/12/2004	 		 		 	Req. Examen	 	23/12/2007	 	
		 		 		 		 		 		 	NZ 548188	 	23/12/2004	 		 		 		 		 	
		 		 		 		 		 		 	US 10/582,131	 	23/12/2004	 		 		 		 		 	
		 		 		 		 		 		 	ZA 2006/06009	 	23/12/2004	 		 		 		 		 	23/12/2009

  

 24 

																									
	 Reference
	 	Titre	 	Dépôt Initial	 	Extension (PCT)	 	Phases nationales	 	Publication de la demande	 	Examens – Annuitées
Échéances
	 	 	 	 	N°	 	Date	 	N°	 	Date	 	Pays	 	Date	 	N°	 	Date	 	Statut	 	Date	 	Annuités
		 	Compounds, preparation and	 	EP 05 291658.2	 	03/08/2005	 		 		 		 		 		 		 		 		 	31/08/2007
		 	Therapeutic use thereof	 		 		 	PCT/IB06/003295	 	02/08/2006	 		 		 		 		 	Phases Nat.
30 mois	 	03/02/2008	 	
	 80305
	 		 		 		 		 		 		 		 		 		 		 		 	
		 	Titulaire	 		 		 		 		 		 		 		 		 		 		 	
		 	NEURO3D	 		 		 		 		 		 		 		 		 		 		 	

  

 25 

 Other assets: 
 Database 
 The VIA.PDE.db is a structure-activity database containing approximately 2,200 compounds with PDE activity. 

 Study reports 
 Volume in drive D is ND1251
pre-clin 
 Volume Serial Number is 696C-4FA6 
 Directory of D:\preclinical 
  

			
	12/19/2006 07:13 AM –	  	
	12/19/2006 07:13 AM –	  	
	12/19/2006 07:13 AM –	  	1251A01_Assays of dosing solutions
	12/19/2006 07:13 AM –	  	1251A02_Interspecies comparison (Biotec)
	12/19/2006 07:13 AM –	  	1251A03_Bioanalytical method
	12/19/2006 07:13 AM –	  	1251A04_Plasma levels in rats
	12/19/2006 07:13 AM –	  	1251A05_Plasma levels in dogs
	 12/19/2006 07:13 AM –
 Plasma
	  	1251A06_Transfer of validation to rabbit
	 12/19/2006 07:13 AM –
 studies in rats
	  	1251A07_Plasma samples analysis of segII
	 12/19/2006 07:13 AM –
 studies in rabbits
	  	1251A08_Plasma samples analysis of segII
	12/19/2006 07:13 AM – method in rat plasma	  	1251A09_Transfer validation of LCMSMS
	12/19/2006 07:13 AM – method in dog plasma	  	1251A10_Transfer validation of LCMSMS
	12/19/2006 07:13 AM – rats	  	1251A11_in vivo ADME_Plasma analysis in
	12/19/2006 07:13 AM – dogs	  	1251A12_in vivo ADME_Plasma analysis in
	12/19/2006 07:13 AM – concentration in rat plasma_Medi	  	1251A13_Determination of ND1251
	12/19/2006 07:13 AM – rat	  	1251A14_Micronucleus_Plasma analysis in
	12/19/2006 07:13 AM –	  	1251A15_Micronucleus_TK in rat
	12/19/2006 07:13 AM –	  	1251H01_Analytical method in human plasma
	12/19/2006 07:13 AM –	  	1251H02_Analytical method in human urine
	12/19/2006 07:13 AM – Concentrations_SD1251C01 in man	  	1251H03_Determination of ND1251
	12/19/2006 07:13 AM –	  	1251H04_Analytical LCMSMS method with
	parent and metabolite in h	  	

  

 26 

			
	12/19/2006 07:13 AM – parent and metabolite in h	  	1251H05_Analytical LCMSMS method with
		
	12/19/2006 07:13 AM – concentrations in MD study 1251C	  	1251H06_Determination of ND1251
		
	12/19/2006 07:13 AM – concentrations in MD study 1251C	  	1251H07_Determination of ND1251
		
	12/19/2006 07:13 AM –	  	1251M01_ADME-tox Profile
		
	12/19/2006 07:13 AM –	  	1251M02_ADME CYP Panel
		
	12/19/2006 07:13 AM – Comparison (Biopredic)	  	1251M03_Interspecies
		
	12/19/2006 07:13 AM –	  	1251M04_CYP inhibition properties
		
	12/19/2006 07:13 AM –	  	1251M05_CYP induction properties
		
	12/19/2006 07:13 AM –	  	1251M06_Identification of CYP involved
		
	12/19/2006 07:13 AM –	  	1251M07_in vivo ADME i.v. & p.o. in rats
		
	12/19/2006 07:13 AM –	  	1251M08_in vivo ADME i.v. & p.o. in dogs
		
	12/19/2006 07:13 AM –	  	1251P01_PDEs inhibition assays
		
	12/19/2006 07:13 AM –	  	1251P02_Carrageenan Edema Test
		
	12/19/2006 07:13 AM –	  	1251P03_In vivo pharmacology
		
	12/19/2006 07:13 AM – molecule ND1251	  	1251P04_Immunosuppressive activity of the
		
	12/19/2006 07:13 AM –	  	1251P05_In vitro pharmacology
		
	12/19/2006 07:13 AM – Central	  	1251P06_IC50 Determination on NK1 and BZD
		
	12/19/2006 07:13 AM –	  	1251P07_plasma binding protein test
		
	12/19/2006 07:13 AM –	  	1251P08_Acute withdrawal Test in rats
		
	12/19/2006 07:13 AM –	  	1251P09_LPS in rat paw
		
	12/19/2006 07:13 AM – admin in mice and rats	  	1251P10_Swim Test after single and acute
		
	12/19/2006 07:13 AM –	  	1251P11_withdrawal effects of ND1251
		
	12/19/2006 07:13 AM – neurite outgrowth	  	1251P12_Effect of ND1251 on hippocampal
		
	12/19/2006 07:13 AM –	  	1251P13_PDE-7 to -11 inhibition assays
		
	12/19/2006 07:13 AM –	  	1251S01_Emesis test in the ferret
		
	12/19/2006 07:13 AM –	  	1251S02 Canal K+ (HERG)
		
	12/19/2006 07:13 AM –	  	1251S03_Irwin test
		
	12/19/2006 07:13 AM –	  	1251S04_Rotarod test in rats
		
	12/19/2006 07:13 AM –	  	1251S05_Activity meter
		
	12/19/2006 07:13 AM –	  	1257S06_Plethysmography in rats
		
	12/19/2006 07:13 AM –	  	1251S07_Purkinje Fibers Test
		
	12/19/2006 07:13 AM –	  	1251S08_Hemodynamic study
		
	12/19/2006 07:13 AM –	  	1251S09_Telemetry
		
	12/19/2006 07:13 AM –	  	1251S10_IC50 determination on Herg Channel
		
	12/19/2006 07:13 AM –	  	1251T01_AMES test
		
	12/19/2006 07:13 AM –	  	1251T02_Genotox chromosome aberration
		
	12/19/2006 07:13 AM –	  	1251T03_Acute tox in mice
		
	12/19/2006 07:13 AM –	  	1251T04_Acute tox in rats

  

 27 

			
	12/19/2006 07:13 AM –	  	1251T05_DRF in rats
		
	12/19/2006 07:13 AM –	  	1251T06_6w tox in Rats
		
	12/19/2006 07:13 AM –	  	1251T07_MTD study in dogs
		
	12/19/2006 07:13 AM –	  	1251T08 6Wtox in Dogs
		
	12/19/2006 07:13 AM – pregnant rabbits	  	1251T09_Escalating RDF study in non-
		
	12/19/2006 07:13 AM – embryo fetal development	  	1251T10_Preliminary study for effects on
		
	12/19/2006 07:13 AM – embryo fetal development	  	1251T11_Preliminary study for effects on
		
	12/19/2006 07:13 AM –	  	1251T12_Principal segt II study in rats
		
	12/19/2006 07:13 AM –	  	1251T13_Principal study in rabbits (SegII)
		
	12/19/2006 07:13 AM –	  	1251T14_in vivo micronucleus in rats

 Volume in drive D is various PDEinhib 
 Volume Serial Number is 69DB-F8FC 
 Directory of D:\preclinical 
  

			
	12/19/2006 07:51 AM –	  	BBBpassage
	12/19/2006 07:51 AM –	  	ND 2698
	12/19/2006 07:51 AM –	  	ND 2945
	12/19/2006 07:51 AM –	  	ND1704
	12/19/2006 07:51 AM –	  	ND2112
	12/19/2006 07:51 AM –	  	ND2700
	12/19/2006 07:51 AM –	  	ND2791
	12/19/2006 07:51 AM –	  	ND3310
	12/19/2006 07:51 AM –	  	ND3661
	12/19/2006 07:51 AM –	  	Single Reports’ various cpds
	12/19/2006 07:51 AM –	  	TNFalphaIC50s
	12/19/2006 07:51 AM –	  	Updated Overview tables

 Volume in drive D is ND1251 clinical 
 Volume Serial Number is DC2B-E8F8 
 Directory of D:\ 
  

			
	12/19/2006 07:29 AM –	  	IB
	12/19/2006 07:29 AM –	  	clinical

  

 28 

 Volume in drive D is ND7001 preclin 
 Volume Serial Number is D683-98F1 
 Directory of D:\ND7001\IB, IMPD, 
  

			
	12/21/2006 05:32 AM –	  	
	12/21/2006 05:32 AM –	  	
	12/21/2006 05:32 AM –	  	IB Edition 1
	12/21/2006 05:32 AM –	  	IB Edition 2
	12/21/2006 05:32 AM –	  	IMPD

 Volume in drive D is ND7001 preclin 
 Volume Serial Number is D683-98F1 
 Directory of D:\ND7001\7001preclinical 
  

			
	12/21/2006 05:32 AM –	  	
	12/21/2006 05:32 AM –	  	
	12/21/2006 05:32 AM –	  	ND7001 safety
	12/21/2006 05:32 AM –	  	ND7001 analytics
	12/21/2006 05:32 AM –	  	ND7001 metaboliskm
	12/21/2006 05:32 AM –	  	ND7001 pharmacology
	12/21/2006 05:32 AM –	  	ND7001 toxicology

  

 29 

 Laboratory Notebooks 
  

							
	LN code	  	Project	  	Unit	  	Order
	2000/38	  	PDE	  	Chemistry	  	1
	2001/02	  	PDE	  	Chemistry	  	1
	2001/04	  	PDE	  	Chemistry	  	2
	2001/08	  	PDE	  	Chemistry	  	1
	2001/08	  	PDE	  	Chemistry	  	2
	2001/12	  	PDE	  	Chemistry	  	1
	2001/12	  	PDE	  	Chemistry	  	3
	2001/20	  	PDE	  	Chemistry	  	1
	2001/20	  	PDE	  	Chemistry	  	4
	2001/71	  	PDE	  	Chemistry	  	1
	2002/33	  	PDE	  	Chemistry	  	1
	2002/34	  	PDE	  	Chemistry	  	5
	2002/40	  	PDE	  	Chemistry	  	1
	2002/46	  	PDE	  	Chemistry	  	2
	2002/51	  	PDE	  	Chemistry	  	6
	2003/03	  	PDE	  	Chemistry	  	1
	2003/06	  	PDE	  	Chemistry	  	2
	2003/09	  	PDE	  	Chemistry	  	3
	2003/16	  	PDE	  	Chemistry	  	7
	2003/17	  	PDE	  	Chemistry	  	3
	2003/19	  	PDE	  	Chemistry	  	2
	2003/20	  	PDE	  	Chemistry	  	1
	2003/24	  	PDE	  	Chemistry	  	4
	4	  	PDE	  	Chemistry	  	
	6	  	PDE	  	Chemistry	  	
	8	  	PDE	  	Chemistry	  	
	11	  	PDE	  	Chemistry	  	
	14	  	PDE	  	Chemistry	  	
	16	  	PDE	  	Chemistry	  	
	19	  	PDE	  	Chemistry	  	
	23	  	PDE	  	Chemistry	  	
	24	  	PDE	  	Chemistry	  	
	26	  	PDE	  	Chemistry	  	
	46	  	PDE	  	Chemistry	  	
	48	  	PDE	  	Chemistry	  	
	52	  	PDE	  	Biology	  	
	53	  	PDE	  	Biology	  	
	56	  	PDE	  	Biology	  	
	57	  	PDE	  	Chemistry	  	
	62	  	PDE	  	Chemistry	  	
	63	  	PDE	  	Chemistry	  	
	72	  	PDE	  	Biology	  	
	73	  	PDE	  	Biology	  	
	74	  	PDE	  	Chemistry	  	
	75	  	PDE	  	Chemistry	  	
	80	  	PDE	  	Chemistry	  	
	81	  	PDE	  	Chemistry	  	
	86	  	PDE	  	Biology	  	
	87	  	PDE	  	Biology	  	
	88	  	PDE	  	Chemistry	  	
	91	  	PDE	  	Chemistry	  	
	93	  	PDE	  	Chemistry	  	
	96	  	PDE	  	Biology	  	

  

 30 

 EXHIBIT A 
 Bill of Sale 
 For good and valuable consideration, the receipt, adequacy and legal sufficiency of
which are hereby acknowledged, and as contemplated by Section 3.2(b) of that certain Patent Rights and Related Assets Purchase Agreement (the “Purchase Agreement”), dated as of January
            , 2007, by and between VIA Pharmaceuticals, Inc., a Delaware corporation having an address of 750 Battery St., Suite 330, San Francisco, California 94111 (the
“Buyer”), and NEURO3D, S.A., a French corporation having an address of 130 rue de la Mer Rouge, F-68200, Mulhouse, France (the “Seller”), Seller hereby sells, transfers, assigns, conveys, grants and delivers to Buyer, effective
as of 10:00 a.m. (New York time) on the date hereof, all of Seller’s right, title and interest in and to all of the patent rights and related assets described on Schedule A hereto (the “Transferred Assets”). 
 Seller covenants and agrees that it will hereafter take all steps reasonably necessary to establish the record of Buyer’s title to the Transferred
Assets and, at the request of Buyer, to execute and deliver further instruments of transfer and assignment and take such other action as Buyer may reasonably request to more effectively transfer and assign to and vest in Buyer each of the
Transferred Assets. 
 Without limiting the foregoing, Seller hereby constitutes and appoints Buyer the true and lawful agent and attorney in
fact of Seller, with full power of substitution and resubstitution, in whole or in part, in the name and stead of Seller but on behalf of and for the benefit of Buyer and its successors and assigns, from time to time: (a) to demand, receive and
collect any and all of the Transferred Assets and to give receipts and releases for and with respect to the same, or any part thereof; (b) to institute and prosecute, in the name of Seller or otherwise, any and all proceedings at law, in equity
or otherwise, that Buyer or its successors and assigns may deem proper in order to collect or reduce to possession any of the Transferred Assets and in order to collect or enforce any claim or right of any kind hereby assigned or transferred, or
intended so to be, and (c) to do all things legally permissible, required or reasonably deemed by Buyer to be required to recover and collect the Transferred Assets and to use Seller’s name in such manner as Buyer may reasonably deem
necessary for the collection and recovery of same, Seller hereby acknowledging that the foregoing powers are coupled with an interest and are and shall be irrevocable by Seller. 
 The terms of the Purchase Agreement are incorporated herein by this reference. In the event of any conflict or inconsistency between the terms of the
Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern. 
  

 31 

 IN WITNESS WHEREOF, Seller has executed this Bill of Sale as of January
            , 2007. 
  

					
	NEURO3D, S.A.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

  

 32 

 SCHEDULE A 
 TRANSFERRED ASSETS 
 See Patent Rights and related asset purchase agreement, Annex 1 which is incorporated herein by
reference. 
  

 33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]